Labiotech.eu

In Depth 12 Jul 2017

Genomic Testing in Oncology: From Single Genes to Whole Genomes

Personalized medicine would be nothing without genomic testing tools. Here’s an overview of how the field has rapidly evolved in the past years. BRCA (BReast CAncer) is one of the most famous gene variants for breast cancer testing. But aside from being a game-changer from a scientific perspective, it also changed the laws of genomic testing. […]

July 12, 2017 - 5 minutesmins - By Timothé Cynober

Interview 11 Jul 2017

The Advantage for the First Mover in NASH is Limited, says Genfit

After we reviewed NASH earlier this year, Genfit’s CSO, Dean Hum, came to speak at Refresh about his company’s strategy in the space. As CSO of Genfit, Dean Hum coordinates the company’s R&D efforts to be first to market in NASH, which represent an untapped market of €37B. The company is counting on its lead […]

July 11, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 11 Jul 2017

Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing

Blueprint Genetics has raised €14M to boost its genetic diagnostics platform, using artificial intelligence to interpret next-generation sequencing data. Based in Helsinki, Finland, Blueprint Genetics is a startup that addresses the main bottleneck of genetic testing through next-generation sequencing (NGS), the interpretation of massive volumes of data, with the aid of artificial intelligence (AI). Its […]

July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Microbiome Diagnostics Partners Enterome Nestle e1517266503234

News and Trends 11 Jul 2017

Enterome and Nestle Launch a New Microbiome Diagnostics Company

Microbiome Diagnostics Partners will develop diagnostics tests with Enterome’s microbiome platform IP and a €20M investment from Nestlé. Nestlé Health Science and Enterome have created Microbiome Diagnostics Partners (MDP) as a joint venture split 50% between both parties. Nestlé has invested €20M for its stake in the new company as well as the exclusive option to commercialize […]

July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 11 Jul 2017

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

Editor’s Note: Novartis did note a death from cerebral hemorrhage in its hearing with the FDA yesterday. With the application review hearing set for tomorrow, the FDA has shared its thoughts on Novartis’ CAR-T candidate. Up front are serious safety concerns. Novartis’ CTL019, or Tisagenlecleucel, wowed the audience at ASH last fall with a stellar 82% […]

July 11, 2017 - 3 minutesmins - By Evelyn Warner

In Depth 11 Jul 2017

Regenerating the Body With Stem Cells – Hype or Hope?

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding. “The overall stem cell therapy field has failed today to show […]

July 11, 2017 - 9 minutesmins - By Melanie De Almeida

News and Trends 10 Jul 2017

You can buy DNA on Amazon, thanks to this Biotech Accelerator

Steve O’Connell from RebelBio spoke to us about how far consumer biotech has come and synbio’s role in its democratization. Steve Jobs famously predicted that biology would one day go the way of computing and become available to the ordinary consumer. How is it progressing? “It’s already happening,” Steve O’Connell, Associate Director of RebelBio, told Philip […]

July 10, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 10 Jul 2017

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat the motor complications of standard levodopa therapy. The Phase II trial will enroll 165 patients across the UK, Germany, France, Austria, Spain and Italy to monitor the effects of Prexton’s foliglurax. The company is looking for patients that have been treated […]

July 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq

Zealand Pharma, known for its partnership with Sanofi to boost the insulin blockbuster Lantus, is aiming high in an IPO on the US Nasdaq. Zealand Pharma has announced it has already filed for an IPO at the Nasdaq Global Select Market, an exclusive listing for large cap companies. Currently listed on the Nasdaq Copenhagen, Zealand Pharma […]

July 10, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the start of a Phase III program that seeks to recruit 250 patients to test its RNAi drug fitusiran in patients with both hemophilia A and […]

July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

This tech not only flags but also identifies and quantifies HCP contaminants

If host cell proteins linger in your biological therapeutic, they can cause your clinical failure or regulatory rejection. Here’s how you can keep track of them. Today, biological drugs are generally produced in cell lines — from yeast, Chinese Hamsters, or a variety of other sources. It’s pretty cool that humans can manipulate these organisms […]

July 10, 2017 - 4 minutesmins - By External Contributor

Minoryx Therapeutics Marc Martinell interview

Interview 10 Jul 2017

Meet the CEO of Minoryx, the Spanish Biotech Fighting Rare Disease

I spoke with Marc Martinell, CEO of Minoryx, to learn first-hand how his company in Barcelona is bringing new hope for patients suffering from rare diseases. Having previously worked in Crystax Pharmaceuticals and Oryzon Genomics, Marc Martinell is now CEO of one of Spain’s most successful biotechs. Minoryx Therapeutics is developing what could be the first […]

July 10, 2017 - 6 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Genomic Testing in Oncology: From Single Genes to Whole Genomes

The Advantage for the First Mover in NASH is Limited, says Genfit

Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing

Enterome and Nestle Launch a New Microbiome Diagnostics Company

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

Regenerating the Body With Stem Cells – Hype or Hope?

You can buy DNA on Amazon, thanks to this Biotech Accelerator

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

This tech not only flags but also identifies and quantifies HCP contaminants

Meet the CEO of Minoryx, the Spanish Biotech Fighting Rare Disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!